Global Scans · Sclerosis · Weekly Summary

• The Department of Defense has anticipated funding opportunities in fiscal year 2025 for research involving Tuberous Sclerosis Complex, vision, and ovarian cancer. Research & Engagement
• Vaccines might one day make multiple sclerosis become a historical disease like polio. Science News
• Products extracted from cannabis will be sold in Spanish pharmacies in order to help alleviate symptoms associated with diseases such as multiple sclerosis, some forms of epilepsy, the side effects of chemotherapy, cancer, chronic pain and endometriosis. The Local
• Another key phase 3 readout Roche expects in 2026 is FENhance 1, the second for fenebrutinib in relapsing multiple sclerosis. Fierce Pharma
• Biogen and its investors also need an aducanumab approval after the company recently lost a patent fight over its big-selling multiple sclerosis drug Tecfidera: If approved, annual sales are forecast to reach $5.3 billion by 2025. U.S.
• Sales are expected to fall in 2026 after growing 2% last year, driven largely by multiple sclerosis drugs losing exclusivity in Europe and facing new competition in the US. The Edge Malaysia
• Biogen is betting that growth from newer drugs - including Alzheimer's treatment Leqembi and rare-disease drugs Skyclarys and Spinraza - will offset its declining multiple sclerosis medicines as competition from generics erode sales. The Edge Malaysia
• The FDA has cleared the initiation of a pivotal, 500-patient, randomized, placebo-controlled phase 3 trial dubbed PREVAiLS, which will assess the efficacy and safety of pridopidine in patients with early-stage, rapidly progressive amyotrophic lateral sclerosis. NeurologyLive - Clinical Neurology News and Neurology E
• Biogen on Monday said it acquired rights to an experimental multiple sclerosis drug from China-based biotech Innocare, investing in a mainstay business for the biotech that has been challenged by competitive threats and patent losses. BioPharma Dive
• In the first half of 2026, the FDA is expected to make a decision on tolebrutinib, an investigational Bruton Tyrosine Kinase (BTK) inhibitor, under review for patients with non-relapsing secondary progressive multiple sclerosis. NeurologyLive - Clinical Neurology News and Neurology E
• A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify patients most likely to benefit from new drugs. News-Medical
• At the country-level, patients in Oman, Kuwait, and Canada had higher risks of secondary progressive multiple sclerosis relative to the other studied regions. OUP Academic

Last updated: 03 August 2026